Aclaris Therapeutics Secures $21M in Series A Financing

Aclaris Therapeutics, Inc., a Malvern, PA-based specialty pharmaceutical company dedicated to developing dermatological therapeutics, has secured $21m in Series A financing.

The round was led by Vivo Ventures and Fidelity Biosciences with participation from Sofinnova Ventures.

Founded in 2012 and led by newly appointed CEO, President and Director Dr. Neal Walker, Chairman of the Board of Directors Stephen Tullman, COO Christopher Powala, Chief Scientific Officer Stuart Shanler, M.D., CFO Frank Ruffo, and Vice President of Clinical Operations Brian Beger, Aclaris Therapeutics focuses on identifying, developing, and commercializing novel topical dermatological technologies.

The company intends to use the proceeds to advance A-101, which is currently a pre-IND asset that is being developed as a topical treatment for both medical and aesthetic indications.

In conjunction with the funding, Albert Cha, M.D., Ph.D., managing partner at Vivo Ventures, and Ketan Patel, M.D., a principal with Fidelity Bioscience, will join Mr. Tullman and Dr. Walker on the Board of Directors of Aclaris.



Join the discussion